Novo Nordisk has unveiled plans to invest $80 million in expanding facilities at its production site in Måløv, Denmark.
 
The facility currently manufactures products for oral diabetes treatments and will be expanded to ensure capacity for future production of these products. The project is expected to be completed in 2022.
 
“This investment in our production facilities in Måløv is an important step in building and ensuring future capacity for production of Rybelsus (oral semaglutide). Måløv is currently our cornerstone in the production of oral semaglutide, and it is critical that we invest timely in capacity expansion to meet the future demands,” said Henrik Steen Jensen, corporate vice president for Novo Nordisk oral semaglutide production.
 
Novo Nordisk’s Måløv site is home to the company’s largest research center in addition to production facilities for both diabetes and biopharmaceutical products. It employs around 700 people at the site.